⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

January 1, 2006Annals of Medicine

Asymmetric dimethylarginine (ADMA): A novel risk marker in cardiovascular medicine and beyond

View Full Paper

Ask AI

Bookmark

Share

Design

Review

Authors

RBRainer H. BögerVascular Medicine

Discussion

Loading...

Member takes

Implication

Hypothesis-generating for ADMA as endothelial marker; L-arginine effects on outcomes require prospective validation.

Key Points

Key points are not available for this paper at this time.

Cite This Study

Rainer H. Böger (2006) studied this question.

synapsesocial.com/papers/6a6f727078a11c550e092790 https://doi.org/10.1080/07853890500472151

Topics

Women and heart disease

View Full Paper

Ask AI

Bookmark

Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Asymmetric Dimethylarginine, C-Reactive Protein, and Carotid Intima-Media Thickness in End-Stage Renal Disease2002 · 322 citations
2Angiotensin-Converting Enzyme Activity is Involved in the Mechanism of Increased Endogenous Nitric Oxide Synthase Inhibitor in Patients With Type 2 Diabetes Mellitus.2002 · 79 citations
3Increased circulating concentrations of asymmetric dimethyl arginine (ADMA), an endogenous inhibitor of nitric oxide synthesis, in preeclampsia1998 · 155 citations
4Effect of High-Dose Statin Treatment on Plasma Concentrations of Endogenous Nitric Oxide Synthase Inhibitors2003 · 78 citations
5Native Low-Density Lipoprotein Increases Endothelial Cell Nitric Oxide Synthase Generation of Superoxide Anion1995 · 475 citations